US EditionPublished • loading... • Updated
GI Innovation Announces First Clinical Supply Agreement to Explore Combination Therapy for Prostate Cancer
GI Innovation's first clinical supply deal aims to advance combination therapy research for prostate cancer, potentially improving treatment options for patients, company said.
- On March 19, 2026, GI Innovation announced a clinical supply agreement with Johnson & Johnson to evaluate a combination therapy in metastatic castration-resistant prostate cancer in a Phase 1b trial.
- Under the supply deal, Johnson & Johnson will provide pasritamig to GI Innovation, which will sponsor the Phase 1b trial testing GI-102 combined with pasritamig, described as a first-in-class KLK2-CD3 bispecific T-cell engager.
- Dr. Mark Stein of Columbia University Irving Medical Center will serve as the global coordinating investigator for the study, which will be conducted in Korea and the United States, including Asan Medical Center and Severance Hospital.
- GI Innovation said this is its first clinical supply agreement to explore combination therapy, and CEO Myoung-ho Jang called the deal "a meaningful step toward validating the potential of GI-102 in combination with next-generation modalities."
- The Phase 1b study aims to evaluate safety and activity of GI‑102 combined with pasritamig in patients with metastatic castration‑resistant prostate cancer, spanning Korea and the United States.
Insights by Ground AI
53 Articles
53 Articles
The Courier-Tribune+51 Reposted by 51 other sources
GI Innovation Announces First Clinical Supply Agreement to Explore Combination Therapy for Prostate Cancer
SEOUL, South Korea, March 19, 2026 /PRNewswire/ -- GI Innovation announced on 19th that it has entered into a clinical supply agreement with Johnson & Johnson to evaluate a combination therapy in patients with metastatic castration-resistant prostate cancer (mCRPC) in…
Coverage Details
Total News Sources53
Leaning Left8Leaning Right7Center17Last UpdatedBias Distribution53% Center
Bias Distribution
- 53% of the sources are Center
53% Center
L 25%
C 53%
R 22%
Factuality
To view factuality data please Upgrade to Premium
